Sign Out
Drug interactions between Filgrastim and other drugs have not been fully evaluated. Drugs which may potentiate the release of neutrophils, such as lithium, should be used with caution.
Toxicology studies: As with other therapeutic proteins, Filgrastim also has a potential for immunogenicity. However, the incidence and effect of this has not been adequately determined. The carcinogenic and mutagenic potential of Filgrastim has not been studied. Single dose acute and chronic toxicity studies were conducted for Filgrastim with intramuscular and subcutaneous dosing in Swiss Albino mice (1000 mcg/kg body weight) and Sprague Dawley rats (500 mcg/kg body weight). The studies revealed no apparent toxicity in the test animals. Filgrastim did not cause any skin sensitization in test animals. It did not induce mutations in the mutagenicity model of Salmonella typhimurium.
Continue with Google